SEC Comment Letter 0000000000-25-001183 to OS Therapies Inc (OSTX)
OS Therapies Inc
Date: Feb. 4, 2025 · CIK: 0001795091 · Accession: 0000000000-25-001183
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284631
Letter
February 4, 2025 Paul A. Romness, MPH President and Chief Executive Officer OS Therapies Incorporated 115 Pullman Crossing Road, Suite #103 Grasonville, Maryland 21638 Re:OS Therapies Incorporated Registration Statement on Form S-1 Filed January 31, 2025 File No. 333-284631 Dear Paul A. Romness MPH: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Spencer G. Feldman, Esq.
Show Raw Text
February 4, 2025
Paul A. Romness, MPH
President and Chief Executive Officer
OS Therapies Incorporated
115 Pullman Crossing Road, Suite #103
Grasonville, Maryland 21638
Re:OS Therapies Incorporated
Registration Statement on Form S-1
Filed January 31, 2025
File No. 333-284631
Dear Paul A. Romness MPH:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Spencer G. Feldman, Esq.